Alzheimer’s disease is the most common type of dementia accounting for 60-80% of cases. In the past 5 years, PRA has conducted numerous clinical trials involving thousands of patients in the effort to fight this devastating disease.

**ACCORDING TO**

Alzheimer’s Disease International’s **WORLD ALZHEIMER REPORT 2015**, the number of people living with Alzheimer’s disease or other dementias will increase to nearly 74.7 million by 2030 and over 131.5 million by 2050.

**STUDY EXPERIENCE IN ALZHEIMER’S DISEASE**

- **58** no. of clinical studies
- **939** no. of clinical sites
- **7469** no. of clinical patients

**WHAT PRA IS DOING TO FIGHT ALZHEIMER’S DISEASE**

- Extensive experience building patient Advisory groups and associations to optimize patient recruitment and site investigations.
- Novel database analytics facilitate strategic country and site selection.
- Potential trial participants and their caregivers receive comprehensive education, communication and support throughout the study.
- Skilled project management and clinical operations staff with up to 30+ years experience.

**COSTS OF CARING FOR PEOPLE WITH ALZHEIMER’S DISEASE**

- In 2016 **$259 billion** is valued at more than **$1.1 trillion** by 2050.
- **18.2 Billion** hours of unpaid care provided.
- The average annual societal costs for Alzheimer’s disease globally is **$219 billion** in 2017 and will rise to **$1.1 trillion** by 2050.

**WHAT WE’RE UP AGAINST**

- Approximately **1 in 9** Americans will develop Alzheimer’s disease.
- **1 in 3** seniors dies with Alzheimer’s disease or another dementia.
- **65** leading cause of death in US.
- **6** in 100,000 individuals under 65 have younger-onset Alzheimer’s Disease.
- **100,000** individuals under 65 have young-onset Alzheimer’s Disease.
- **1 in 3** for 60-80% of cases. In the past 5 years, PRA has conducted numerous clinical trials involving thousands of patients in the effort to fight this devastating disease.
- **65** seniors dies with Alzheimer’s disease or another dementia.
- **Alzheimer's disease** is the most common type of dementia accounting for 60-80% of cases. In the past 5 years, PRA has conducted numerous clinical trials involving thousands of patients in the effort to fight this devastating disease.

**WHAT PRA IS DOING TO FIGHT ALZHEIMER’S DISEASE**

- **58** no. of clinical studies
- **939** no. of clinical sites
- **7469** no. of clinical patients

**PRA IS PARTICIPATING IN A GROUNDBREAKING ALZHEIMER’S DISEASE STUDY THAT IS AT THE CORNERSTONE OF THE NEW ALZHEIMER’S PREVENTION INITIATIVE AND COULD LEAD TO TREATMENTS DELAYING OR PREVENTING SYMPTOMS IN PEOPLE GENETICALLY PREDISPOSED TO THE DISEASE**

**WHAT WE’RE UP AGAINST**

- Approximately **1 in 9** Americans will develop Alzheimer’s disease.
- **1 in 3** seniors dies with Alzheimer’s disease or another dementia.
- **65** leading cause of death in US.
- **6** in 100,000 individuals under 65 have younger-onset Alzheimer’s Disease.
- **100,000** individuals under 65 have young-onset Alzheimer’s Disease.
- **1 in 3** for 60-80% of cases. In the past 5 years, PRA has conducted numerous clinical trials involving thousands of patients in the effort to fight this devastating disease.
- **65** seniors dies with Alzheimer’s disease or another dementia.
- **Alzheimer's disease** is the most common type of dementia accounting for 60-80% of cases. In the past 5 years, PRA has conducted numerous clinical trials involving thousands of patients in the effort to fight this devastating disease.